Furthermore, inhibiting the PI3K/Akt pathway has been shown to reduce the expression of neuroendocrine tumor markers, such as ASCL1 and CgA in pancreatic BON1 cells (166) – this is potentially clinically relevant, as targeting the PI3K/Akt pathway may not only limit tumor cell proliferation or survival, but could conceivably control the troublesome symptoms resulting from hormone oversecretion (166). Here, AKT1 is linked to neoplasm.